Fukui Pharmaceutical's "Pilacitin Injection" has been approved for listing.

Intelligence Finance and Economics APP News, Forsen Pharmaceutical (01652.HK) announced that the market application for the "Piracetam Injection" developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has been approved by the China National Medical Products Administration. It is approved for use in various causes of memory decline and mild to moderate brain dysfunction caused by acute and chronic cerebrovascular diseases, traumatic brain injury, various toxic brain diseases, and can also be used for children with delayed intellectual development.